Home Journals Articles Updates About
CN
image
收藏切换
Mobocertinib succinate: a novel drug for targeted therapy of lung cancer patients with EGFR exon 20 insertion mutation
收藏切换
PDF
Zhi-xiang XIONG1, Zhi-feng WANG2, Jing YU3, Lu HUANG4, Yi HONG1
Chinese Journal of New Drugs | 2023, 32(8) : 777 - 782
Less
收藏切换
Chinese Journal of New Drugs | 2023, 32(8): 777-782
Mobocertinib succinate: a novel drug for targeted therapy of lung cancer patients with EGFR exon 20 insertion mutation
Full
Zhi-xiang XIONG1, Zhi-feng WANG2, Jing YU3, Lu HUANG4, Yi HONG1
Affiliations
  • 1School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China
  • 2Yingshan People's Hospital, Hubei Province, Huanggang 438700, China
  • 3Wuhan QR Pharmaceuticals Co., Ltd., Wuhan 430200, China
  • 4Guangzhou Wellhealth Bio-pharma Co., Ltd., Guangzhou 510200, China
Published: 2023-04-30
Outline
收藏切换

Mobocertinib succinate is a novel and potent tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR). On September 15, 2021, it was approved by U.S. FDA for the first time, and the brand name is Exkivity. It is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation, whose disease has progressed on or after platinum-based chemotherapy. This article introduces the drug's mechanism of action, pharmacokinetics, pharmacodynamics, clinical evaluation studies, and safety.

mobocertinib  /  epidermal growth factor receptor tyrosine kinase inhibitor  /  exon 20 insertion mutation  /  non-small cell lung cancer  /  clinical study
Zhi-xiang XIONG, Zhi-feng WANG, Jing YU, Lu HUANG, Yi HONG. Mobocertinib succinate: a novel drug for targeted therapy of lung cancer patients with EGFR exon 20 insertion mutation[J]. Chinese Journal of New Drugs, 2023 , 32 (8) : 777 -782 .
Appendix
Less
Year 2023 volume 32 Issue 8
PDF
27
6
Cite this Article
BibTeX
Article Info
  • Online Date：2026-03-06
  • Published：2023-04-30
Article Data
Affiliations
History
  • Accepted：2022-09-19
Funding
Affiliations
    1School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China
    2Yingshan People's Hospital, Hubei Province, Huanggang 438700, China
    3Wuhan QR Pharmaceuticals Co., Ltd., Wuhan 430200, China
    4Guangzhou Wellhealth Bio-pharma Co., Ltd., Guangzhou 510200, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House